Impaired interleukinhyphen;12 production is associated with a defective antihyphen;tumor response in colorectal cancer

摘要

INTRODUCTIONcolon;Despite development of many chemotherapeutic regimens, colorectal cancer continues to have a high mortality. One of the major new potential therapies is interleukinhyphen;12, a heterodimeric cytokine produced by antigen presenting cells.In vitroandin vivostudies have demonstrated the role of interleukinhyphen;12 in stimulating a cellhyphen;mediated antihyphen;tumor response against a number of colon adenocarcinoma tumor models. However, it is unknown whether patients with colorectal cancer have impaired interleukinhyphen;12 production. A study was performed to investigate production of interleukinhyphen;12 preoperatively and the relationship between these levels and disease stage at surgery.METHODScolon;Preoperative peripheral blood mononuclear cells from colorectal cancer patients and agematched controls were stimulated byStaphylococcus aureusCowan's Strain 1 lpar;0.0075 percent wtsol;volrpar;in vitrofor 24 hours. Expression of interleukinhyphen;12 was then assessed by enzymehyphen;linked immunosorbent assay. A single pathologist assessed the tumors for stage according to TNM and Dukes classifications.RESULTScolon;Twentyhyphen;eight patients with colorectal cancer and 14 controls were recruited for the study. Interleukinhyphen;12 production was significantly impaired in patients with colorectal cancer compared with controls lpar;Pequals;0.014rpar;, especially those with advanced diseasecolon; Dukes C,Pequals;0.001 and T4,P0.05.CONCLUSIONcolon;Interleukinhyphen;12 production is impaired in patients with colorectal cancer, especially those with advanced disease, suggesting a defective Th1hyphen;mediated antihyphen;tumor response. These patients may well benefit from exogenous interleukinhyphen;12 treatment.